The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...

Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Ho Chi Minh City plans to pilot mechanisms for pharmaceutical companies to adopt digital technologies, showcasing its ...

CAG reported handling a total of 1.99 million tonnes of airfreight in 2024, up 14.6 per cent from 2023. Read more at straitstimes.com.

(Legal Fee Tracker is a weekly feature focused on attorney compensation. Please send tips or suggestions to ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...